Brokerages Set Flexion Therapeutics, Inc. (NASDAQ:FLXN) PT at $19.70


Share on StockTwits

Flexion Therapeutics, Inc. (NASDAQ:FLXN) has been assigned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $20.00.

Several brokerages recently commented on FLXN. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 16th. Wells Fargo & Company cut their price objective on shares of Flexion Therapeutics from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, January 27th. Credit Suisse Group cut their price objective on shares of Flexion Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, March 17th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Flexion Therapeutics in a report on Monday, December 14th.

Shares of FLXN stock traded down $0.04 during midday trading on Thursday, hitting $8.30. 618,822 shares of the company were exchanged, compared to its average volume of 766,753. The firm has a market capitalization of $414.37 million, a P/E ratio of -2.68 and a beta of 1.64. The company has a debt-to-equity ratio of 12.77, a quick ratio of 4.31 and a current ratio of 4.66. The firm’s 50 day moving average price is $10.54 and its two-hundred day moving average price is $11.44. Flexion Therapeutics has a 52 week low of $7.52 and a 52 week high of $14.39.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Tuesday, March 9th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.07. Analysts expect that Flexion Therapeutics will post -2.6 EPS for the current year.

In other news, insider Melissa Layman sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, January 28th. The shares were sold at an average price of $12.55, for a total value of $32,931.20. Following the completion of the transaction, the insider now directly owns 91,000 shares in the company, valued at approximately $1,142,050. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 17.03% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the company. Eudaimonia Partners LLC acquired a new position in shares of Flexion Therapeutics in the 3rd quarter valued at approximately $36,000. UBS Asset Management Americas Inc. raised its position in shares of Flexion Therapeutics by 12.3% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 46,524 shares of the specialty pharmaceutical company’s stock valued at $484,000 after buying an additional 5,092 shares in the last quarter. BlackRock Inc. increased its position in Flexion Therapeutics by 20.1% during the 3rd quarter. BlackRock Inc. now owns 4,123,141 shares of the specialty pharmaceutical company’s stock worth $42,923,000 after purchasing an additional 691,089 shares in the last quarter. EMC Capital Management acquired a new position in Flexion Therapeutics during the 4th quarter worth approximately $297,000. Finally, Snow Capital Management LP increased its position in Flexion Therapeutics by 1.0% during the 4th quarter. Snow Capital Management LP now owns 306,265 shares of the specialty pharmaceutical company’s stock worth $3,534,000 after purchasing an additional 3,000 shares in the last quarter.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Read More: EV Stocks

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.